Eko Welcomes Chris Economos as Vice President of Life Sciences

Economos, an AI-based clinical technology leader, joins the company to expand global life science partnerships

Eko Welcomes Chris Economos as Vice President of Life Sciences

Oakland, California
June 3, 2022

Eko announces the appointment of Chris Economos as Vice President and Head of Life Sciences. Economos will spearhead Eko’s efforts in cultivating strategic and commercial relationships with medical technology and pharmaceutical companies. His role will accelerate clinical research and product development collaborations with life science companies to drive earlier disease detection, enhanced virtual care, and optimized clinical research initiatives.  

Chris joins Eko from physIQ Inc., where, as SVP of Corporate Development, he oversaw corporate partnerships, M&A activities, and innovation. Chris established physIQ’s life sciences business, and under his leadership, the Janssen Pharmaceutical Companies of Johnson & Johnson selected physIQ as a global partner for data analytics. Prior to physIQ, Chris’s professional experience includes Healthy Interactions, Abbvie, ZymoGenetics, and Deloitte. He holds a Bachelor of Science degree from Vanderbilt University and an MBA from the Indiana University Kelley School of Business.

“Eko has developed an intelligent stethoscope platform to detect cardiovascular and pulmonary disease earlier, giving patients more timely access to life-saving treatments,” said Jason Bellet, Co-Founder and Chief Strategy Officer of Eko. “We’re thrilled to welcome Chris Economos as Vice President of Life Sciences to further expand our strategic partnerships with medical technology and pharmaceutical companies that share our vision for closing the gap between detection and intervention.”

Chris joins Eko during a year of significant milestones. In January, the NHS published a landmark independent study validating Eko’s ability to quickly screen patients, using proprietary AI, for heart failure during routine physical exams. The company was named one of the “10 most innovative medical device company of 2022” and was awarded a “World Changing Idea” by Fast Company. Additionally, Eko was recognized for AI Innovation in Healthcare and named to the list of “Best Workplaces” for 2022 by Inc.

“Almost a decade ago, I made the leap into digital medicine because I believed it was the future of healthcare,” said Economos. “Eko is one of the companies that has created that future by digitizing clinical signals at the point of care in a way unmatched in the industry. This unprecedented access to digital clinical data is an incredible asset that I am passionate about bringing to life science companies that have a shared belief in the power of AI.”

Looking for a career to put your heart into and join an Inc. Magazine “Best Workplaces”? Learn more about Eko’s open roles at https://www.ekohealth.com/page/careers.

Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

Eko Devices, Inc.
1212 Broadway, Suite 100
Oakland, CA 94612

Eko Team
Content & Press
Sign up for a Demo
A member of our team will respond with one business day.